Literature DB >> 25430879

Type I IFN gene delivery suppresses regulatory T cells within tumors.

H Hashimoto1, R Ueda1, K Narumi1, Y Heike2, T Yoshida3, K Aoki1.   

Abstract

Type I interferon (IFN) is a pleiotropic cytokine regulating the cancer cell death and immune response. IFN-α can, as we have also reported, effectively induce an antitumor immunity by the activation of tumor-specific T cells and maturation of dendritic cells in various animal models. Unknown, however, is how the type I IFN alters the immunotolerant microenvironment in the tumors. Here, we found that intratumoral IFN-α gene transfer significantly decreased the frequency of regulatory T cells (Tregs) per CD4(+) T cells in tumors. The concentration of a Treg-inhibitory cytokine, interleukin (IL)-6, was correlated with the IFN-α expression level in tumors, and intratumoral CD11c(+) cells produced IL-6 in response to IFN-α stimulation. To confirm the role of IL-6 in the suppression of Tregs in tumors, an anti-IL-6 receptor antibody was administered in IFN-α-treated mice. The antibody increased the frequency of Tregs in the tumors, and attenuated systemic tumor-specific immunity induced by IFN-α. Furthermore, the IFN-α-mediated IL-6 production increased the frequency of Th17 cells in the tumors, which may be one of the mechanisms for the reduction of Tregs. The study demonstrated that IFN-α gene delivery creates an environment strongly supporting the enhancement of antitumor immunity through the suppression of Tregs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25430879     DOI: 10.1038/cgt.2014.60

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  47 in total

Review 1.  Targeting regulatory T cells in cancer.

Authors:  William L Byrne; Kingston H G Mills; James A Lederer; Gerald C O'Sullivan
Journal:  Cancer Res       Date:  2011-11-08       Impact factor: 12.701

2.  Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma.

Authors:  Ajai Chari; Hadass Pri-Chen; Sundar Jagannath
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-01-10

3.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

Review 4.  Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

Authors:  Joannes F M Jacobs; Stefan Nierkens; Carl G Figdor; I Jolanda M de Vries; Gosse J Adema
Journal:  Lancet Oncol       Date:  2012-01       Impact factor: 41.316

5.  Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer.

Authors:  Yuqi Guo; Jeffrey Nemeth; Colin O'Brien; Michiro Susa; Xianzhe Liu; Zhan Zhang; Edwin Choy; Henry Mankin; Francis Hornicek; Zhenfeng Duan
Journal:  Clin Cancer Res       Date:  2010-08-10       Impact factor: 12.531

6.  IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer.

Authors:  Sergei Grivennikov; Eliad Karin; Janos Terzic; Daniel Mucida; Guann-Yi Yu; Sivakumar Vallabhapurapu; Jürgen Scheller; Stefan Rose-John; Hilde Cheroutre; Lars Eckmann; Michael Karin
Journal:  Cancer Cell       Date:  2009-02-03       Impact factor: 31.743

7.  A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.

Authors:  J-F Rossi; S Négrier; N D James; I Kocak; R Hawkins; H Davis; U Prabhakar; X Qin; P Mulders; B Berns
Journal:  Br J Cancer       Date:  2010-08-31       Impact factor: 7.640

8.  FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

Authors:  Noritoshi Kobayashi; Nobuyoshi Hiraoka; Wataru Yamagami; Hidenori Ojima; Yae Kanai; Tomoo Kosuge; Atsushi Nakajima; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.

Authors:  Kazuteru Hatanaka; Koichi Suzuki; Yoshiaki Miura; Kimiko Yoshida; Shumpei Ohnami; Yukio Kitade; Teruhiko Yoshida; Kazunori Aoki
Journal:  J Gene Med       Date:  2004-10       Impact factor: 4.565

10.  Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential.

Authors:  C A Mullen; M M Coale; A T Levy; W G Stetler-Stevenson; L A Liotta; S Brandt; R M Blaese
Journal:  Cancer Res       Date:  1992-11-01       Impact factor: 12.701

View more
  17 in total

Review 1.  Type I interferons in anticancer immunity.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2015-06-01       Impact factor: 53.106

2.  Single-cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing.

Authors:  Ashley R Hoover; Kaili Liu; Christa I DeVette; Jason R Krawic; Alexandra D Medcalf; Connor L West; Tomas Hode; Samuel S K Lam; Alana L Welm; Xiao-Hong Sun; William H Hildebrand; Wei R Chen
Journal:  Clin Transl Med       Date:  2022-07

3.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 4.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 5.  The Effects of Interferons on Allogeneic T Cell Response in GVHD: The Multifaced Biology and Epigenetic Regulations.

Authors:  Chenchen Zhao; Yi Zhang; Hong Zheng
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

6.  Cycling CD4+ T cells in HIV-infected immune nonresponders have mitochondrial dysfunction.

Authors:  Souheil-Antoine Younes; Aarthi Talla; Susan Pereira Ribeiro; Evgeniya V Saidakova; Larisa B Korolevskaya; Konstantin V Shmagel; Carey L Shive; Michael L Freeman; Soumya Panigrahi; Sophia Zweig; Robert Balderas; Leonid Margolis; Daniel C Douek; Donald D Anthony; Pushpa Pandiyan; Mark Cameron; Scott F Sieg; Leonard H Calabrese; Benigno Rodriguez; Michael M Lederman
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 19.456

Review 7.  Type I Interferons and Natural Killer Cell Regulation in Cancer.

Authors:  Lena Müller; Petra Aigner; Dagmar Stoiber
Journal:  Front Immunol       Date:  2017-03-31       Impact factor: 7.561

Review 8.  Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease.

Authors:  Lindsey E Fox; Marissa C Locke; Deborah J Lenschow
Journal:  Front Immunol       Date:  2020-12-21       Impact factor: 7.561

Review 9.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

10.  Local memory CD4 T cell niches in respiratory viral infection.

Authors:  Kurt B Pruner; Marion Pepper
Journal:  J Exp Med       Date:  2021-06-23       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.